Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873102 · ClinicalTrials.gov registry record · Phase 2
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
A Phase 2 study of Cirrhosis, Liver and Cytopenia, sponsored by University of Southern California.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04873102: Recruiting Phase 2 study of Cirrhosis, Liver and Cytopenia, sponsored by University of Southern California.
NCT04873102 is a Phase 2 study of Cirrhosis, Liver and Cytopenia that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 10 participants, below the 242-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873102, a Phase 2 study of Cirrhosis, Liver and Cytopenia, is actively recruiting participants, sponsored by University of Southern California.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients.
Primary Outcome
Defined as normalization of WBC to ≥ 4000/µL or doubling of WBC from baseline, AND/OR normalization of platelet count to ≥150,000/µL or doubling of platelet count from baseline, from study entry to three months.
Conditions Studied
Interventions
- DRUG Danazol Pill
Study Locations (1)
California
- Keck Hosital of USC - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
What NCT04873102 shows while recruiting
NCT04873102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 242-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which Danazol Pill is the first listed.
NCT04873102 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04873102 about?
NCT04873102 is a clinical study titled "Danazol for Treatment of Cytopenias in Patients With Cirrhosis". This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months...
What is the current status of trial NCT04873102?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2024-08-01. Estimated completion is 2027-08-01.
What conditions does trial NCT04873102 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Cytopenia.
What interventions are being tested in trial NCT04873102?
The interventions under investigation include: Danazol Pill (DRUG).
Who is sponsoring clinical trial NCT04873102?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04873102's enrollment target sits among peer trials
10 33rd of 34 higher than 2 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
RECRUITING · Phase 2
-
EGCG for Hepatocellular Carcinoma Chemoprevention
RECRUITING · Phase 2
-
Liver Cancer Disparities in American Indian and Alaska Native Persons
RECRUITING · Phase 2
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI